Tag Archives: Edward Nash

Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (NASDAQ: MDGL), Zentalis Pharmaceuticals (NASDAQ: ZNTL) and Outlook Therapeutics (NASDAQ: OTLK)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Madrigal Pharmaceuticals (MDGL – Research Report), Zentalis Pharmaceuticals (ZNTL – Research Report) and Outlook Therapeutics (OTLK – Research Report) with bullish sentiments.

Intercept Pharma (ICPT) Receives a Hold from Canaccord Genuity

Canaccord Genuity analyst Edward Nash maintained a Hold rating on Intercept Pharma (ICPT – Research Report) yesterday and set a price target of $58.00. The company’s shares closed last Tuesday at $52.58, close to its 52-week low of $42.19. According

Madrigal Pharmaceuticals (MDGL) Receives a Buy from Canaccord Genuity

In a report released yesterday, Edward Nash from Canaccord Genuity maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report), with a price target of $198.00. The company’s shares closed last Tuesday at $104.06. According to TipRanks.com, Nash is

Analysts Offer Insights on Healthcare Companies: Theratechnologies (NASDAQ: THTX), Misonix (NASDAQ: MSON) and Zymeworks (NYSE: ZYME)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Theratechnologies (THTX – Research Report), Misonix (MSON – Research Report) and Zymeworks (ZYME – Research Report) with bullish sentiments. Theratechnologies (THTX) Canaccord

Analysts Offer Insights on Healthcare Companies: Theratechnologies (NASDAQ: THTX) and Ascendis Pharma (NASDAQ: ASND)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Theratechnologies (THTX – Research Report) and Ascendis Pharma (ASND – Research Report) with bullish sentiments. Theratechnologies (THTX) Canaccord Genuity analyst Edward Nash

Analysts Offer Insights on Healthcare Companies: Akero Therapeutics (NASDAQ: AKRO), Cara Therapeutics (NASDAQ: CARA) and BioMarin Pharmaceutical (NASDAQ: BMRN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Akero Therapeutics (AKRO – Research Report), Cara Therapeutics (CARA – Research Report) and BioMarin Pharmaceutical (BMRN – Research Report) with bullish sentiments.